Skip to content
About Us
Company Profile
History
Management
Investors
Research & Development
Mode of Action
Clinical Development
Publications
Vascular Integrity
Adrenomedullin
Sepsis & Septic Shock
News & Events
Contact
Menu
About Us
Company Profile
History
Management
Investors
Research & Development
Mode of Action
Clinical Development
Publications
Vascular Integrity
Adrenomedullin
Sepsis & Septic Shock
News & Events
Contact
Article in BioWorld: Adrenomed’s adrecizumab shows hints of efficacy in open-label COVID-19 study
28. August 2020
August 2020,
by Cormac Sheridan
Read the full article
here
.